At the end of September 2, 14,436,431 doses administered with the Cuban vaccines Soberana 02 and Soberana Plus, and with the Cuban vaccine Abdala, have accumulated in the country.
To date, 5,714,552 people have received at least one dose of SOBERANA 02 or Abdala. 4,671,645 people already have a second dose and 4,050,234 people have a third dose.
Mass vaccination
Infographic: Minsap
–
The Center for the State Control of Medicines, Equipment and Medical Devices (CECMED) on July 9 decided to grant the Authorization of Emergency Use (AUE) to the Cuban vaccine Abdala 50 µg, whose owner is the Center for Genetic Engineering and Biotechnology CIGB , in accordance and in observance of the provisions of the regulations and provisions in force, once it has been confirmed that the requirements and parameters demanded in terms of quality, safety and efficacy for this type of procedure were met.
Start date: July 29, 2021
Participants:
- Population over 19 years of age in territories with epidemiological risk and risk groups at the level of all provinces.
Total doses administered during Mass Vaccination: 4 330 916
Sanitary Intervention
Infographic: Minsap
–
Since the beginning of May, the Minister of Public Health, backed by Article 64 of Law 41 “Public Health Law” of July 13, 1983, approved a health intervention with Cuban vaccine candidates Abdala and Soberana 02 in risk groups and territories.
Start date: May 2021
Participants:
- Health workers, BioCubaFarma, Medical Sciences students and other risk groups.
- Population of territories at risk selected by stages.
Total doses administered during the Health Intervention: 9 503 783
Intervention Study
Infographic: Minsap
–
As part of the research associated with the Cuban vaccine candidates Soberana 02 and Abdala, an intervention study was carried out in risk groups, aimed at subjects in risk groups and who could provide relevant data.
Start date: March 2021
Participants:
- Health workers, BioCubaFarma and other risk groups.
- Territories where the study was applied: Havana, Santiago de Cuba, Granma and Guantánamo.
Total doses administered during the Intervention Study: 452 368
Clinical trials
Infographic: Minsap
–
The development of clinical trials with the Cuban vaccine candidates Soberana 02, Abdala and Soberana Plus (for convalescents) was approved by the Center for State Control of Medicines, Equipment and Medical Devices (CECMED) and implemented in volunteer subjects from selected territories.
Start date: March 2021
Participants:
- Volunteer subjects selected by the researchers.
- Territories where the tests were applied: Havana, Santiago, Granma and Guantánamo.
Total doses administered during the Clinical Trials: 149,364 (the doses of placebos administered during the Clinical Trials are excluded from this figure).
(Taken from Minsap Cuba)
– .
